CN104039777B - 帕罗西汀衍生物 - Google Patents

帕罗西汀衍生物 Download PDF

Info

Publication number
CN104039777B
CN104039777B CN201380005183.XA CN201380005183A CN104039777B CN 104039777 B CN104039777 B CN 104039777B CN 201380005183 A CN201380005183 A CN 201380005183A CN 104039777 B CN104039777 B CN 104039777B
Authority
CN
China
Prior art keywords
compound
acceptable salt
pharmacologically acceptable
paroxetine
examples
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380005183.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN104039777A (zh
Inventor
田中圭悟
西岡大貴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanitary Material R&d Management Co ltd
Original Assignee
Sanitary Material R&d Management Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanitary Material R&d Management Co ltd filed Critical Sanitary Material R&d Management Co ltd
Publication of CN104039777A publication Critical patent/CN104039777A/zh
Application granted granted Critical
Publication of CN104039777B publication Critical patent/CN104039777B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380005183.XA 2012-01-31 2013-01-29 帕罗西汀衍生物 Expired - Fee Related CN104039777B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261592896P 2012-01-31 2012-01-31
US61/592896 2012-01-31
US61/592,896 2012-01-31
PCT/JP2013/051858 WO2013115163A1 (ja) 2012-01-31 2013-01-29 パロキセチン誘導体

Publications (2)

Publication Number Publication Date
CN104039777A CN104039777A (zh) 2014-09-10
CN104039777B true CN104039777B (zh) 2016-03-02

Family

ID=48870749

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380005183.XA Expired - Fee Related CN104039777B (zh) 2012-01-31 2013-01-29 帕罗西汀衍生物

Country Status (16)

Country Link
US (1) US8933100B2 (enExample)
EP (1) EP2810942B1 (enExample)
JP (1) JP6055784B2 (enExample)
KR (1) KR101950057B1 (enExample)
CN (1) CN104039777B (enExample)
AR (1) AR089837A1 (enExample)
AU (1) AU2013216123B2 (enExample)
BR (1) BR112014016197A8 (enExample)
CA (1) CA2861479C (enExample)
ES (1) ES2576082T3 (enExample)
IL (1) IL233327A (enExample)
IN (1) IN2014CN04922A (enExample)
MX (1) MX355654B (enExample)
RU (1) RU2616610C2 (enExample)
TW (1) TW201334783A (enExample)
WO (1) WO2013115163A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3344248B1 (en) * 2015-09-02 2022-03-23 Trevena, Inc. 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
CN110446495B (zh) 2017-02-17 2023-09-05 特维娜有限公司 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
CN111533682B (zh) * 2020-05-29 2022-03-01 清华大学 帕罗西汀及其类似物的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056787A1 (en) * 1997-06-10 1998-12-17 Synthon B.V. 4-Phenylpiperidine compounds
CN101273024A (zh) * 2005-07-29 2008-09-24 康瑟特制药公司 新颖苯并[d][1,3]-二氧杂环戊烯衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
IT1308629B1 (it) * 1999-02-23 2002-01-09 Recordati Chem Pharm Processo per la produzione di paroxetina.
US20070142389A1 (en) * 2005-12-20 2007-06-21 Pfizer Inc. Piperidine derivatives
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056787A1 (en) * 1997-06-10 1998-12-17 Synthon B.V. 4-Phenylpiperidine compounds
CN101273024A (zh) * 2005-07-29 2008-09-24 康瑟特制药公司 新颖苯并[d][1,3]-二氧杂环戊烯衍生物

Also Published As

Publication number Publication date
AR089837A1 (es) 2014-09-17
MX2014007620A (es) 2014-09-15
JP6055784B2 (ja) 2016-12-27
KR101950057B1 (ko) 2019-02-19
WO2013115163A1 (ja) 2013-08-08
US8933100B2 (en) 2015-01-13
EP2810942B1 (en) 2016-03-30
CA2861479A1 (en) 2013-08-08
KR20140117454A (ko) 2014-10-07
BR112014016197A2 (pt) 2017-06-13
CA2861479C (en) 2017-10-10
RU2014126321A (ru) 2016-03-20
ES2576082T3 (es) 2016-07-05
JPWO2013115163A1 (ja) 2015-05-11
US20130197033A1 (en) 2013-08-01
EP2810942A4 (en) 2015-07-01
RU2616610C2 (ru) 2017-04-18
AU2013216123A1 (en) 2014-07-17
BR112014016197A8 (pt) 2017-07-04
AU2013216123B2 (en) 2016-10-20
IL233327A (en) 2016-03-31
EP2810942A1 (en) 2014-12-10
IL233327A0 (en) 2014-08-31
CN104039777A (zh) 2014-09-10
IN2014CN04922A (enExample) 2015-09-18
MX355654B (es) 2018-04-26
TW201334783A (zh) 2013-09-01

Similar Documents

Publication Publication Date Title
CN116370479B (zh) 化合物atv014在制备用于治疗新冠病毒感染的产品中的用途
KR20080080195A (ko) 크로메인 치환된 벤즈이미다졸 및 이들의 산 펌프억제제로서의 용도
US20060293343A1 (en) Pyrimidine derivatives
CN104039777B (zh) 帕罗西汀衍生物
CN106565674B (zh) 一种八氢环戊烷并[c]吡咯衍生物及其制备方法和在医药上的用途
CN104039781B (zh) 西他生坦衍生物
WO2013115167A1 (ja) アムバチニブ誘導体
Chen et al. Mycophenolic acid analogs with a modified metabolic profile
CN116768881B (zh) 4-(3-吲哚基)-1,3-噻唑类化合物及其制备方法和应用
WO2024159211A1 (en) Methods and compositions for treatment of obesity and diseases associated with fat cell enlargement
Gaali Design and Synthesis of Selective Ligands for the FK506-binding Protein 51
BR112017001554B1 (pt) Di-hidropirimidinonas bicíclicas substituídas, seu sal, composição farmacêutica que os compreende e seu uso como inibidores de atividade da elastase neutrófila

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160302

Termination date: 20210129